Newsbriefs: Breast Cancer Treatment

Pathway to Treatment for Triple-Negative Breast Cancer.

A key to unlocking treatment for a very aggressive form of breast cancer may soon be within researchers’ grasps. The cancer, in which tumors do not express estrogen receptor, progesterone receptor, or genes that promote production of the HER2 protein, is called triple negative breast cancer, and is responsible for 10 to 20 percent of invasive breast cancer diagnoses. A team from the University of Freiburg, Germany, is leading the new study for treatment of this type of cancer. The researchers have shown that inhibiting the epigenetic regulator KDM4 may offer potential treatment. The treatment model enables researchers to develop “cancer stem-like cells”—cells similar to normal stem cells in the body, but which promote cancerous activity. Researchers have isolated these cells from human breast cancer tumors and developed an in vitro (laboratory) model, enabling them to test several epigenetic inhibitors on the cancer stem cell model. Of these, the KDM4 was the most promising in blocking proliferation of several cancer stem cell lines. Study findings were published in Cancer Research, October 2017.

The post Newsbriefs: Breast Cancer Treatment appeared first on University Health News.

Read Original Article: Newsbriefs: Breast Cancer Treatment »

Powered by WPeMatico